Comment from Unlearn.AI

Summary: Unlearn.AI, a technology company specializing in AI-based digital twins for clinical trials, supports the FDA's pilot program to optimize early-phase clinical trials. They propose specific use cases, including digital twin efficacy benchmarks and real-time trial simulations, to improve decision-making, shorten development timelines, and enhance data quality.